North, I don't have access to CNBC's Melissa Lee's special re Risky RX. If any topic is mentioned that would enlighten us AMRN shareholders since we are dealing with generics made away from the USA, please pass it along. Thanks
Yeah, AMRN doesn't really qualify as risky any more. It's not even a biotech any more, not really.
It's more like a software company with a single, incredible app with a crazy good patent mote. They have 20 employees, sit back and license the thing out, and just rake in cash with very little expense.
It's not in the IBB, and IBB isn't a good index to measure it against.
Market Data 
Markets 
AI
